Loading clinical trials...

Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer | Clinical Trials | Clareo Health

TERMINATEDPhase 2NCT01069796

Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

Patients with triple negative metastatic breast cancer (HER2-, PR-, ER-) will receive bevacizumab, paclitaxel and capecitabine as a first line of treatment (possibility to have received adjuvant chemo...

Lead sponsor: ARCAGY/ GINECO GROUP•17 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Related studies

TERMINATEDPhase 1

Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer

NCT02358200 · Triple Negative Metastatic Breast Cancer, BRCA-mutated Solid Tumor

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 17, 2016Terms

Trial snapshot

StatusTERMINATED

PhasePHASE2

Enrollment64

Start dateApr 2010

Last updatedMar 17, 2016

Condition

Triple Negative Metastatic Breast Cancer

Locations shown

Centre Paul Papin

Angers

Clinique Tivoli

Bordeaux

Centre Hospitalier William Morey

Chalon-sur-Saône

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 17, 2016Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions